As of August 12, 2026, Odyssey Therapeutics, Inc. (ODTX) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Odyssey Therapeutics, Inc. has a market capitalization of $802.43M, 48.03M shares outstanding.
This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.
Score Breakdown
🔄Convertible Debt—
Dilution Forecast
☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ODTX.
Market Data
Market Cap$802.43M
Shares Outstanding48.03M
Float11.59M
Cash$175.75M
Debt$34.38M
Short InterestN/A
Institutional Holdings
38.4% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
Short Interest
Short Interest2.27M
Days to Cover9.7
% of Float19.6%
FINRA data as of Jul 31, 2026
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2026-06-30
xbrl
XBRL WARRANT
2026-06-30
4
INSIDER TRANSACTION
2026-05-13
4
INSIDER TRANSACTION
2026-05-12
3
FORM3
2026-05-12
Full SEC filing analysis available with free account
→
Recent News
No recent news
Factual ODTX Dilution Snapshot
Odyssey Therapeutics, Inc. (ODTX) has a DilutionScore of 52/100, rated High dilution risk. Score date: August 12, 2026.
- Recent SEC activity tracked for ODTX: xbrl on 2026-06-30; xbrl on 2026-06-30; 4 on 2026-05-13.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Track ODTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ODTX — Free
Real-time SEC alerts
DilutionScore™ tracking
No credit card required
More Research for ODTX
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.